Loading
Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma.
Quincy Chu is a medical oncologist at the Cross Cancer Institute in Edmonton and a thoracic disease site leader in the Canadian Cancer Trials Group. He was first author of the 2023 Lancet report of IND.227/KEYNOTE-483, the international phase 3 trial in which pembrolizumab plus platinum-pemetrexed chemotherapy improved overall survival compared with chemotherapy alone in untreated unresectable pleural mesothelioma, leading to the combination's approval.
| Title | Journal | Year |
|---|---|---|
| KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma | The Lancet | 2023 |
Shares the tags mesothelioma, immunotherapy.
Shares KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma, Pleural mesothelioma.
Shares the tags mesothelioma, immunotherapy.
Shares the tags immunotherapy, trialist.
Shares the tags immunotherapy, trialist.
Shares the tags immunotherapy, trialist.
Shares the tags immunotherapy, trialist.
Shares the tags immunotherapy, trialist.